NCT06632600 - A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

March 22, 2027

Study Completion Date

September 22, 2027

Conditions

Chagas Disease

Interventions

DRUG

LXE408

LXE408 administered by oral route

DRUG

Placebo

Placebo administered by oral route

DRUG

Benznidazole

Benznidazole administered by oral route (administered as standard of care)

Trial Locations (17)

1407

RECRUITING

Novartis Investigative Site, CABA

3600

RECRUITING

Novartis Investigative Site, Formosa

91342

RECRUITING

Olive View UCLA Educ and Res Ins, Sylmar

110110

RECRUITING

Novartis Investigative Site, Bogotá

110131

RECRUITING

Novartis Investigative Site, Bogotá

681017

RECRUITING

Novartis Investigative Site, Floridablanca

684031

RECRUITING

Novartis Investigative Site, San Gil

850009

RECRUITING

Novartis Investigative Site, Yopal

02118

RECRUITING

Boston Medical Center, Boston

77030-3411

RECRUITING

Baylor College of Medicine, Houston

C1221ADC

RECRUITING

Novartis Investigative Site, CABA

W3400

RECRUITING

Novartis Investigative Site, Corrientes

X5016KEH

RECRUITING

Novartis Investigative Site, Córdoba

39401-001

RECRUITING

Novartis Investigative Site, Montes Claros

21040-360

RECRUITING

Novartis Investigative Site, Rio de Janeiro

09521-160

RECRUITING

Novartis Investigative Site, São Caetano do Sul

080005

RECRUITING

Novartis Investigative Site, Barranquilla